The University of Louisville Infectious Diseases Laboratory followed the US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) guidance for developing a molecular diagnostic test for SARS CoV-2 to help address the novel coronavirus pandemic. As a Clinical Laboratory Improvement Amendment ‘88 (CLIA) certified, high-complexity clinical laboratory, the Infectious Diseases Laboratory chose to use the Luminex ARIES® platform to evaluate a laboratory developed test. This instrument was already familiar to the Infectious Diseases Laboratory and in use for molecular diagnostic testing for pathogens causing atypical pneumonia and two tick-borne pathogens. The FDA EUA guidance for molecular diagnostic tests recommended limit of detection studies, inclusivity and exclusivity (specificity) analysis, and validation with clinical samples to ensure the performance of the assay was acceptable for use as a molecular diagnostic tool. Data obtained from these experiments demonstrated acceptable performance per FDA guidance, as well as for CLIA requirements. Thus, the real-time Reverse Transcription PCR assay was implemented for diagnostic use on March 27, 2020 and was a great benefit to the local community in responding to the pandemic.
"The author(s) received no specific funding for this work".
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Marimuthu, Subathra; Aliesky, Holly; Connelly, Brigid; Malik, Danial Arsalan; and Wolf, Leslie A
"Development of a real-time Reverse-Transcription PCR for SARS CoV-2 on the Luminex ARIES® Platform,"
The University of Louisville Journal of Respiratory Infections: Vol. 5
, Article 10.
Available at: https://ir.library.louisville.edu/jri/vol5/iss1/10